BcFG is coming closer to reality everyday. 1. Land purchase is nearing completion -> will start building. 2. CDMO of interest identified for particular drug formulations and administration routes. 3. Potential venture capitol investors communicating with. 4. Business is set to become a reality once Land purchase is closed. 5. Trademark and copyright will be next. 6. Licensing of the patent to BcFG from myself. 7. Finalization of venture capitol and CDMO partners. 8. Clinical trials 9. FDA approval 10. Market - We will also be selling antiseptics without FDA approval meant for surface disinfection.(but if you chose to use them on yourself could work as a topical, but would be strongly discouraged) #BcFG #antibiotics #antiseptics #business #venturecapitol #venture #money #funding #invest #investment #changetheworld #licensing #clinicaltrials #drugs #steps #stepbystep #makingprogress #alwaysprogressing
Ryan B.’s Post
More Relevant Posts
-
This year the Life Sciences Strategy Summit on IP & Exclusivity will have a Pre-Event SPC & PTE Forum on October 8! Discuss the updates and strategies concerning SPCs and PTEs, during this exclusice unique gathering of pharma and biotech regulatory, in-house counsel and private practice specialists. Update your life science exclusivity strategy for 2024 as you deep dive into these topics and more! - SPC Waiver Litigation Update and its Impact on the Generic and Innovator Landscape. - CJEU opinion for C-119/22 and C-149/22. - An update on the Unitary SPC proposal and how to update your European patenting strategy. - SPCs 101- What every patent practitioner needs to know about SPCs. Discover everything on offer during the pre-day and full event by viewing the agenda here: https://lnkd.in/g9ZCamBp #lifescience #SPC #regulatory #PTE #Litigation
-
-
All eyes are on pharma’s pricing freedom. Companies now have 30 days to withdraw or amend their patent listings, or “certify under penalty or perjury” that the patents are proper. Partner & Director of Life Sciences Katherine Rubino weighs in on what this could mean for drug-price in 2024. Learn more from Fierce Pharma: https://lnkd.in/ewrdqeg3
-
-
🎉 Exciting News! 🎉 We're incredibly proud to announce that the USPTO has officially awarded us a patent for our innovative "System And Method For Safe And Accurate Self Administration Of Medications" (U.S. Patent Number: 11,869,645). 🚀 Our proprietary medication engine and digital tools utilize this intellectual property. This milestone is more than just an accolade; it's another stepping stone towards revolutionizing comprehensive medication management. We're eager to engage in discussions about how we can empower pharmacists and patients to optimize medication therapies like never before. 💡👥 Let's explore the future of healthcare together! #InnovationInHealthcare #DigitalHealth #USPTO #PatentedTechnology #MedicationManagement #PharmacyTech #PatientCare #IlluminateHealth
-
-
FTC Supports March-In Rights to Control Prices and Stimulate Competition: The Federal Trade Commission (FTC) has waded into the march-in rights fracas, supporting the obscure Bayh-Dole Act as a tool to moderate drug pricing and control patent thickets on drugs developed with federal funding. #fda #financial #lifesciences
-
Directors John Covert and Gaby Longsworth, Ph.D. presented the webinar “Patent Term Extension Considerations for BioPharma Patents,” which covered the interplay between PTE, Patent Term Adjustment (PTA), and obviousness-type double patenting (ODP) as well as strategies for choosing a patent to extend; managing multiple PTE requests; the pitfalls of interim extensions; and the provisions and responsibilities of the USPTO and FDA. Read our webinar Q&A highlights and watch the On-Demand recording to learn more about the intricacies of patent term extension procedures and strategy in the life sciences industry, and how an extended patent relates to overall exclusivity. #PTE #biopharma
Patent Term Extension Considerations for BioPharma Patents | Sterne Kessler
-
Dive into this week's DrugPatentWatch highlights and stay informed on the latest drug patent news and insights. Don't miss out on critical updates that could impact your business strategies. Stay ahead of the curve with our in-depth analysis and expert commentary. #DrugPatentWatch #PharmaNews #PatentUpdates #IndustryInsights #BusinessStrategy
-
-
Directors John Covert and Gaby L. Longsworth presented the webinar “Patent Term Extension Considerations for BioPharma Patents,” which covered the interplay between PTE, Patent Term Adjustment (PTA), and obviousness-type double patenting (ODP) as well as strategies for choosing a patent to extend; managing multiple PTE requests; the pitfalls of interim extensions; and the provisions and responsibilities of the USPTO and FDA. Read our webinar Q&A highlights and watch the On-Demand recording to learn more about the intricacies of patent term extension procedures and strategy in the life sciences industry, and how an extended patent relates to overall exclusivity. #PTE #biopharma
-
Senior Marketing Manager, Leading Content Development and Strategic Marketing and Communications Campaigns
Watch our recent webinar replay On-Demand—John Covert and Gaby L. Longsworth offer some unique insights/best practices for PTE strategies in the biopharma space. #biopharma #patentlaw
Directors John Covert and Gaby L. Longsworth presented the webinar “Patent Term Extension Considerations for BioPharma Patents,” which covered the interplay between PTE, Patent Term Adjustment (PTA), and obviousness-type double patenting (ODP) as well as strategies for choosing a patent to extend; managing multiple PTE requests; the pitfalls of interim extensions; and the provisions and responsibilities of the USPTO and FDA. Read our webinar Q&A highlights and watch the On-Demand recording to learn more about the intricacies of patent term extension procedures and strategy in the life sciences industry, and how an extended patent relates to overall exclusivity. #PTE #biopharma
-
FDA Rethinking Automatic 30-Month Stay in Patent Thickets After Endo Sues: A new chapter emerged this week in the contentious issue of patent thickets, a web of overlapping patents filed on a single existing product to create barriers to competition and extend effective patent life. #fda #financial #lifesciences
FDA Rethinking Automatic 30-Month Stay in Patent Thickets After Endo Sues
fdanews.com
-
In a new article, #FrierLevitt attorneys delve into the pitfalls and compliance considerations #Pharmacies and #Physicians must know when prescribing, compounding and dispensing semaglutide for weight loss. Read here:
Prescribing, Compounding and Dispensing Semaglutide for Weight Loss: The Pitfalls and Compliance Considerations for Pharmacies and Physicians
